Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Clinical characteristics of the 51 recurrent or metastatic breast cancers

From: Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer

Characteristic at initial diagnosis Number of patients %
Total 51 100
Median age (years) 53.4 (32 to 79)  
Median follow-up time (months) 51.7 (0.9 to 256)  
Stage   
   I to III 34 67
   IV 17 33
Estrogen receptor   
   Positive 32 63
   Negative 17 33
   Missing 2 4
Human epidermal growth factor receptor 2  
   Positive 15 29
   Negative 33 65
   Missing 3 6
PIK3CA mutation 16 31